Publications by authors named "G Garaulet"
The combination of immunoPET-where an antibody (Ab) is labeled with an isotope for PET imaging-and radioimmunotherapy (RIT), using the same antibody with a therapeutic isotope, offers significant advantages in cancer management. ImmunoPET allows non-invasive imaging of antigen expression, which aids in patient selection for subsequent radioimmunotherapy. It also facilitates the assessment of tumor response to therapy, allowing for treatment adjustments if necessary.
View Article and Find Full Text PDFPurpose: Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that lacks effective diagnostic and therapeutic options. Membrane type 1 matrix metalloproteinase (MT1-MMP) is an attractive biomarker for improving patient selection. This study aimed to develop a theranostic tool using a highly tumour-selective anti-MT1-MMP antibody (LEM2/15) radiolabelled with Zr for PET and Lu for therapy in a TNBC murine model.
View Article and Find Full Text PDFTriple-negative breast cancer (TNBC) is characterized by aggressiveness and high rates of metastasis. The identification of relevant biomarkers is crucial to improve outcomes for TNBC patients. Membrane type 1-matrix metalloproteinase (MT1-MMP) could be a good candidate because its expression has been reported to correlate with tumor malignancy, progression and metastasis.
View Article and Find Full Text PDFArticle Synopsis
- Centrosome function is crucial for proper chromosome segregation, and abnormalities in centrosomes relate to primary autosomal microcephaly (MCPH), especially affecting neural progenitors.
- The centrosomal kinase PLK1 plays a significant role in maintaining centrosome asymmetry and influencing cell fate during neural progenitor development, with mutations leading to varying impacts on centrosome behavior.
- Deficiencies in MCPH genes can increase centrosome asymmetry and microcephaly, while reduced PLK1 activity promotes neural progenitor expansion and abnormal cortical growth, indicating a fragile balance in centrosomal regulation that could link to neurodevelopmental issues in children.
Interleukin 12 is a promising anti-cancer agent; however, IL12 systemic administration is hampered by side-effects. Although intratumoral administration of IL12 is giving promising results in clinical trials, only a small percentage of patients show a complete therapeutic response. This outcome could be improved by controlling the IL12 expression window.
View Article and Find Full Text PDF